
David John DeBrota MD
Medical Fellow at Eli Lilly and Company
Join to View Full Profile
Lilly Corporate CtrIndianapolis, IN 46285
Phone+1 317-276-3239
Fax+1 317-433-2815
Dr. DeBrota is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Indiana University School of MedicineResidency, Internal Medicine, 1983 - 1989
- Indiana University School of MedicineClass of 1983
Certifications & Licensure
- IN State Medical License 1984 - 2025
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 2 citationsSerum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1Jennifer Leohr, Debra Luffer-Atlas, M. Jane Luo, David J. DeBrota, Colin F. Green
Journal of Clinical Pharmacology. 2018-04-01 - 24 citationsBaseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.Yuval A. Patel, Joanne C. Imperial, Andrew J. Muir, Quentin M. Anstee, David J. DeBrota
Gastroenterology. 2017-09-01 - 26 citationsPharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjectsChristopher D. Payne, Mark A. Deeg, Melanie Chan, Lai Hock Tan, Elizabeth Smith Labell
British Journal of Clinical Pharmacology. 2014-12-01
Press Mentions
- Perspectum Announces FDA Grant Award for LiverMultiScan to Help NASH PatientsSeptember 17th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: